share_log

Purple Biotech Analyst Ratings

Benzinga ·  Aug 30, 2023 23:20
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/30/2023 662.71% HC Wainwright & Co. $7 → $9 Maintains Buy
07/21/2023 577.97% JonesTrading → $8 Initiates Coverage On → Buy
05/17/2023 493.22% HC Wainwright & Co. → $7 Reiterates Buy → Buy
05/17/2023 832.2% Chardan Capital → $11 Reiterates Buy → Buy
02/09/2023 493.22% HC Wainwright & Co. → $7 Reiterates → Buy
02/09/2023 832.2% Chardan Capital → $11 Reiterates → Buy
10/17/2022 493.22% HC Wainwright & Co. → $7 Initiates Coverage On → Buy
09/08/2022 832.2% Chardan Capital → $11 Initiates Coverage On → Buy

What is the target price for Purple Biotech (PPBT)?

The latest price target for Purple Biotech (NASDAQ: PPBT) was reported by HC Wainwright & Co. on August 30, 2023. The analyst firm set a price target for $9.00 expecting PPBT to rise to within 12 months (a possible 662.71% upside). 8 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Purple Biotech (PPBT)?

The latest analyst rating for Purple Biotech (NASDAQ: PPBT) was provided by HC Wainwright & Co., and Purple Biotech maintained their buy rating.

When is the next analyst rating going to be posted or updated for Purple Biotech (PPBT)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Purple Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Purple Biotech was filed on August 30, 2023 so you should expect the next rating to be made available sometime around August 30, 2024.

Is the Analyst Rating Purple Biotech (PPBT) correct?

While ratings are subjective and will change, the latest Purple Biotech (PPBT) rating was a maintained with a price target of $7.00 to $9.00. The current price Purple Biotech (PPBT) is trading at is $1.18, which is out of the analyst's predicted range.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment